Discontinuation of Antiretroviral Therapy in Patients With Asymptomatic HIV Infection

This study has been completed.
Sponsor:
Information provided by:
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00050284
First received: December 3, 2002
Last updated: November 5, 2010
Last verified: November 2010
  Purpose

The purpose of this study is to determine whether patients who have asymptomatic HIV infection can discontinue antiretroviral therapy (ART) without adverse clinical, virologic, or immunologic consequences. This study will also assess the virologic, immunologic, and clinical outcomes in any patients who restart ART.


Condition
HIV Infections

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Predictors of Immunologic and Clinical Progression in Subjects With CD4+ Cell Counts Greater Than 350 Cells/mm3 Who Discontinue Antiretroviral Therapy

Resource links provided by NLM:


Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Estimated Enrollment: 158
Detailed Description:

Patients who can discontinue ART without a significant loss of virologic or immunologic control and without an increase in clinical events may be spared the expense and adverse effects of treatment. However, the consequences of treatment discontinuation in patients with asymptomatic HIV infections are not well understood. This study will follow the clinical and immunologic progression of HIV infection in patients who have low HIV viral load and preserved CD4+ cell counts at the time ART is stopped.

Patients will fast for at least 8 hours prior to the first study visit. At this visit, blood will be drawn and body measurements will be taken. Patients will then discontinue their ART. Patients taking nonnucleoside reverse transcriptase inhibitors (NNRTIs) will stop taking NNRTIs 48 hours before withdrawing their other ART drugs. Study visits will occur every 4 to 8 weeks for the first year, then every 12 weeks for the second year. Blood will be taken at most visits, and patients will be asked to fast for at least 8 hours prior to Week 12 and 24 visits and again every 6 months. Patients who reinitiate ART for any reason will be registered to Step 2 and followed for 24 weeks.

  Eligibility

Ages Eligible for Study:   13 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • HIV infection
  • ART with 2 or more drugs for 6 or more months
  • CD4+ cell count(s) > 350 cells/mm3 immediately prior to initiation of first ART
  • CD4+ cell count > 350 cells/mm3 within 45 days prior to study entry
  • Plasma viral load < 55,000 copies/ml within 45 days prior to study entry
  • Willingness to discontinue ART at study entry
  • Negative serum or urine pregnancy test within 14 days prior to study entry

Exclusion Criteria:

  • Pregnancy or breast-feeding
  • Systemic cancer chemotherapy, systemic investigational agents, or immunomodulators within 30 days prior to study entry
  • Drug or alcohol use or dependence that would interfere with adherence to study requirements
  • Illness requiring systemic treatment and/or hospitalization until the patient either completes therapy or has been clinically stable on therapy for at least 30 days prior to study entry
  • Chronic medical condition that would have a negative impact on the participation of the patient or would be expected to result in significant use of the medical care system
  • History of an HIV-related illness or complication in CDC categories B and C
  • Nonadherence to ART
  • Active infection with hepatitis B and currently taking adefovir at doses > 10 mg or 3TC and/or TDF
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00050284

  Show 34 Study Locations
Sponsors and Collaborators
Investigators
Study Chair: Daniel J. Skiest, M. D. University of Texas Southwestern Medical Center
  More Information

Additional Information:
Publications:
ClinicalTrials.gov Identifier: NCT00050284     History of Changes
Other Study ID Numbers: ACTG A5170
Study First Received: December 3, 2002
Last Updated: November 5, 2010
Health Authority: United States: Federal Government

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Treatment Experienced
Disease Progression
Anti-HIV Agents
Treatment Interruption

Additional relevant MeSH terms:
Infection
Communicable Diseases
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases

ClinicalTrials.gov processed this record on October 01, 2014